Moving Biotech gets Health Canada approval to initiate phase 2a INFLAM MOTION clinical trial for knee osteoarthritis: Lille & Paris, France Saturday, March 29, 2025, 17:00 Hrs [I ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the drugs are not intended for everyone and may be used by some patients ...

LINCOLN, Neb. (KOLN) - Popular GLP-1 drugs have been gaining traction across the United States as a means for weight loss. The drug has been approved to help treat type-2 diabetes, but a new study ...

CHICAGO, IL—The pool of patients who could potentially benefit from a glucagon-like peptide 1 (GLP-1) receptor agonist has expanded, thanks to new data showing that people with diabetes and ...

The SOUL (NCT03914326) clinical trial is the first to assess the cardiovascular benefits of an oral GLP-1 inhibitor, building on its effectiveness aligns with injectable formulations.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

RSPR Invesco S&P 500 Equal Weight Real Estate ETF ...

In simple terms, having more weight can throw off hormones that promote a regular period and help you get pregnant—so, with losing weight on a GLP-1, those hormones can potentially get back to ...